CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
89Zr-daratumumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03665155
NCT03665155Phase 2Completed
CompareCT.gov

First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody

Memorial Sloan Kettering Cancer Center·interventional·Posted Sep 11, 2018·Updated Jul 30, 2021

In Brief

A Phase 2 clinical trial evaluating 89Zr-daratumumab, PET/CT scans, and 1 other intervention for Multiple Myeloma. Completed, enrolled 11 participants across 1 site.

Detailed Summary

The purpose of this study is to test 89Zr-DFO-daratumumab, a new imaging agent, to demonstrate its safety and ability to take pictures of the myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 11, 2018
Enrollment StartSep 5, 2018
Primary CompletionApr 20, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.8 years ago

Interventions

89Zr-daratumumabdrug

2 mCi of 89Zr-daratumumab will be administered on day 0.

PET/CT scansdevice

PET/CT images will be obtained on post-administration days 1, 2-4, 5-6, and/or 7-8 following administration of 89Zr-DFO-daratumumab to determine the optimal time point for imaging.

Blood drawsother

Blood and serum samples will be weighed and counted in a scintillation well counter calibrated for 89Zr. Immediately before or after each PET/CT imaging session,